Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2377-2380

  Saif, Muhammad Wasif ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aflibercept; Antiangiogenesis; Bevacizumab; MCRC; Regorafenib; TKI; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACENTAL GROWTH FACTOR; PLATINUM; REGORAFENIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ANGIOGENESIS; APPETITE DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DYSPHONIA; EPISTAXIS; FATIGUE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY CARCINOMA; LIVER METASTASIS; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; ORAL MUCOSITIS; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SIDE EFFECT; THROMBOSIS; WEIGHT REDUCTION; ANTIANGIOGENIC ACTIVITY; COLORECTAL TUMOR; DRUG ANTAGONISM; MCRC; TKI; TREATMENT OUTCOME;

AFLIBERCEPT; ANTIANGIOGENESIS; BEVACIZUMAB; MCRC; REGORAFENIB; TKI; VEGF;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; PHENYLUREA COMPOUNDS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84881356162     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. American Cancer Society. Cancer Facts & Figures 2013 Atlanta, GA: American Cancer Society; 2013.
2. Saif MW and Mehra R: Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 5(4): 553-66, 2006.
3. Li J and Saif MW: Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics pp. 429-441, 2009.
4. Hurwitz H, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
5. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB: Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22: 23-30, 2004.
7. Arnold D, Andre T, Bennouna J, Sastre J, Osterlund PJ, Greil R, Van Cutsem E, Von Moos R, Reyes-Rivera I, Bendahmane B and Kubicka S: Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 30: suppl; abstr CRA3503, 2012.
8. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S and Wolmark N: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29: 11-16, 2011.
9. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R and Allegra C: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 30(28): 3499-3506, 2012.
10. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A and Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863): 303-312, 2013.
11. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003.
12. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
13. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 355:2542-2550, 2006.
14. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD and Wen PY: Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29(19): 2689-95, 2011.
15. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA and Herbst RS: A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-And erlotinibresistant adenocarcinoma of the lung. J Thorac Oncol 5(7): 1054-1059, 2010.
16. Tew WP, Colombo N, Ray-Coquard I: VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25(suppl 18S): 276s, abstr 5508, 2007.
17. Tarhini AA, Christensen S and Frankel P: Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol 27(suppl 15S): 468s, abstr 9028, 2009.
18. Kim ES, Serur A, Huang J: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99: 11399-11404, 2002.